Literature DB >> 31301487

The two-stage placental model of preeclampsia: An update.

Anne Cathrine Staff1.   

Abstract

Early-onset preeclampsia has been linked to poor placentation and fetal growth restriction, whereas late-onset preeclampsia was suggested to result from maternal factors. We have proposed an alternative model, suggesting that both early- and late-onset preeclampsia result from placental syncytiotrophoblast stress. This stress represents a common endpoint of several Stage 1 processes, promoting the clinical stage 2 of preeclampsia (new-onset hypertension and proteinuria or other signs of end-organ dysfunction), but the causes and timing of placental malperfusion differ. We have suggested that late-onset preeclampsia, without evidence of poor spiral artery remodelling, may be secondary to intraplacental (intervillous) malperfusion due to mechanical restrictions. As the growing placenta reaches its size limit, malperfusion and hypoxia occurs. This latter pathway reflects what is observed in postmature or multiple pregnancies. Our revised two-stage model accommodates most risk factors for preeclampsia including primiparity, chronic pre-pregnancy disease (e.g. obesity, diabetic-, chronic hypertensive-, and some autoimmune diseases), and pregnancy risk factors (e.g. multiple or molar pregnancies, gestational diabetes or hypertension, and low circulating Placental Growth Factor). These factors may increase the risk of progressing to the second stage of preeclampsia (both early- and late-onset) by affecting one of or both pathways leading to Stage 1, as well as potentially accelerating the steps towards Stage 2, including priming the maternal cardiovascular susceptibility to inflammatory factors shed by the placenta. This paper reviews previous preeclampsia findings and concepts, which fit with the revised two-stage model, and argues that "maternal" preeclampsia does not exist, as all preeclampsia requires a placenta.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Hypertension; Immunology; Pathophysiology; Placenta; Preeclampsia; Pregnancy; Spiral artery; decidua

Mesh:

Year:  2019        PMID: 31301487     DOI: 10.1016/j.jri.2019.07.004

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  64 in total

Review 1.  Sleep Disordered Breathing, a Novel, Modifiable Risk Factor for Hypertensive Disorders of Pregnancy.

Authors:  Laura Sanapo; Margaret H Bublitz; Ghada Bourjeily
Journal:  Curr Hypertens Rep       Date:  2020-03-12       Impact factor: 5.369

2.  Neuro-oncological Ventral Antigen 2 Regulates Splicing of Vascular Endothelial Growth Factor Receptor 1 and Is Required for Endothelial Function.

Authors:  Veerle Kremer; Jetta J Oppelaar; Theresa Gimbel; Susanne Koziarek; Wessel Ganzevoort; Mariëlle G van Pampus; Bert-Jan van den Born; Liffert Vogt; Christianne de Groot; Reinier A Boon
Journal:  Reprod Sci       Date:  2022-08-04       Impact factor: 2.924

3.  Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension.

Authors:  Chaitra Banala; Sindy Moreno; Yury Cruz; Rupsa C Boelig; Gabriele Saccone; Vincenzo Berghella; Corina N Schoen; Amanda Roman
Journal:  Am J Obstet Gynecol       Date:  2020-03-12       Impact factor: 8.661

4.  Dysfunction of Decidual Macrophages Is a Potential Risk Factor in the Occurrence of Preeclampsia.

Authors:  Miaomiao Rong; Xingyu Yan; Hongya Zhang; Chan Zhou; Cong Zhang
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

Review 5.  Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.

Authors:  S Suvakov; C Richards; V Nikolic; T Simic; K McGrath; A Krasnodembskaya; L McClements
Journal:  Curr Hypertens Rep       Date:  2020-04-14       Impact factor: 5.369

Review 6.  Maternal microvascular dysfunction during preeclamptic pregnancy.

Authors:  Anna E Stanhewicz; Virginia R Nuckols; Gary L Pierce
Journal:  Clin Sci (Lond)       Date:  2021-05-14       Impact factor: 6.876

7.  Assessment of All-Cause Cancer Incidence Among Individuals With Preeclampsia or Eclampsia During First Pregnancy.

Authors:  Chris Serrand; Thibault Mura; Pascale Fabbro-Peray; Gilles Seni; Ève Mousty; Thierry Boudemaghe; Jean-Christophe Gris
Journal:  JAMA Netw Open       Date:  2021-06-01

8.  Analysis of perinatal coagulation function in preeclampsia.

Authors:  Chang Xu; YunHui Li; Wen Zhang; QiuShi Wang
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

9.  Genotypic analysis of the female BPH/5 mouse, a model of superimposed preeclampsia.

Authors:  Jenny L Sones; Christina C Yarborough; Valerie O'Besso; Alexander Lemenze; Nataki C Douglas
Journal:  PLoS One       Date:  2021-07-16       Impact factor: 3.240

Review 10.  Prothrombotic state associated with preeclampsia.

Authors:  Cha Han; Yuan-Yuan Chen; Jing-Fei Dong
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.